PSP Research LLC
Filing Date
Global Rank
#7,563
/ 8,517
▲ 174
Top Industry
Biotechnology
91.7%
3Y Alpha vs SPY
+36.9%
Period ended 47 days ago
Filed Jul 9, 2026 · 38d
3 quarters · since Dec 2025
Clone Performance
Feb 2026–Aug 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+26.9%
SPY
+13.9%
Annualised alpha
+31.2%
Max drawdown
−8.7%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends; a captured split can shorten the simulated window. It tracks 100% of reported value on average across 3 quarters. Past performance does not predict future results.
Portfolio Concentration
73 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
2.3%
−11.9 pts
Top 5
11.0%
−10.2 pts
Top 10
21.4%
−7.5 pts
HHI
156
Diversified−155
Portfolio Trend
3 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $27,210,699 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
Trimmed
Positions the filer reduced
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | −53,000 | 18,000 | $254,700 | |
| DFTX | Definium Therapeutics, Inc. | −24,800 | 10,000 | $470,400 | |
| ARDX | Ardelyx, Inc. | −20,000 | 60,000 | $306,000 | |
| NTLA | Intellia Therapeutics, Inc. | −6,900 | 20,000 | $338,400 | |
| IMVT | Immunovant, Inc. | −6,200 | 13,000 | $500,890 | |
| RARE | Ultragenyx Pharmaceutical Inc. | −5,100 | 17,000 | $567,630 | |
| VKTX | Viking Therapeutics, Inc. | −5,000 | 10,000 | $390,100 | |
| PHVS | Pharvaris N.V. | −5,000 | 15,000 | $518,700 | |
| GLUE | Monte Rosa Therapeutics, Inc. | −5,000 | 23,000 | $556,600 | |
| CRSP | CRISPR Therapeutics AG | −4,500 | 5,000 | $272,700 | |
| TNGX | Tango Therapeutics, Inc. | −4,400 | 10,000 | $312,600 | |
| HRMY | Harmony Biosciences Holdings, Inc. | −4,283 | 10,000 | $364,100 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | −4,000 | 5,000 | $319,750 | |
| KOD | Kodiak Sciences Inc. | −4,000 | 6,000 | $233,760 | |
| EXEL | Exelixis, Inc. | −3,948 | 8,000 | $435,280 | |
| NRIX | Nurix Therapeutics, Inc. | −3,700 | 25,000 | $606,500 | |
| VERA | Vera Therapeutics, Inc. | −3,000 | 7,000 | $300,370 | |
| TGTX | Tg Therapeutics, Inc. | −3,000 | 10,000 | $549,400 | |
| BBIO | BridgeBio Pharma, Inc. | −3,000 | 3,000 | $223,440 | |
| NAMS | NewAmsterdam Pharma Co N.V. | −3,000 | 12,000 | $406,680 | |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | −2,500 | 2,500 | $243,700 | |
| MIRM | Mirum Pharmaceuticals, Inc. | −2,500 | 2,500 | $292,675 | |
| KYMR | Kymera Therapeutics, Inc. | −2,300 | 4,000 | $458,680 | |
| IMNM | Immunome Inc. | −2,000 | 18,000 | $381,420 | |
| ORKA | Oruka Therapeutics, Inc. | −1,968 | 3,000 | $285,510 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
10 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| LQDA | Liquidia Corp | 5,000 | $398,650 | |
| KRYS | Krystal Biotech, Inc. | 692 | $257,195 | |
| AVBP | ArriVent BioPharma, Inc. | 7,041 | $244,604 | |
| JAZZ | Jazz Pharmaceuticals plc | 971 | $233,981 | |
| RVMD | Revolution Medicines, Inc. | 1,200 | $224,736 | |
| RYTM | Rhythm Pharmaceuticals, Inc. | 2,000 | $222,060 | |
| DNLI | Denali Therapeutics Inc. | 8,463 | $217,668 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 2,600 | $211,926 | |
| SRRK | Scholar Rock Holding Corp | 3,827 | $210,485 | |
| CTMX | CytomX Therapeutics, Inc. | 39,400 | $147,750 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
14 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| SERA | Sera Prognostics, Inc. | 2,396,685 | $4,865,270 | |
| TYRA | Tyra Biosciences, Inc. | 16,000 | $612,800 | |
| CYTK | Cytokinetics Inc | 8,300 | $547,053 | |
| AGIO | Agios Pharmaceuticals, Inc. | 15,000 | $507,450 | |
| PRAX | Praxis Precision Medicines, Inc. | 1,500 | $483,285 | |
| INBX | Inhibrx Biosciences, Inc. | 6,927 | $465,702 | |
| ERAS | Erasca, Inc. | 17,327 | $280,350 | |
| CELC | Celcuity Inc. | 2,000 | $228,280 | |
| LEGN | Legend Biotech Corp | 12,000 | $217,080 | |
| APGE | Apogee Therapeutics, Inc. | 2,500 | $210,425 | |
| UTHR | UNITED THERAPEUTICS Corp | 350 | $207,543 | |
| SMMT | Summit Therapeutics Inc. | 10,223 | $193,828 | |
| CMPX | Compass Therapeutics, Inc. | 30,000 | $158,700 | |
| KALV | KalVista Pharmaceuticals, Inc. | 10,795 | $0 | |
| No positions match the current search. | ||||
73 tracked positions ·
$27,210,699 total
· as of Jun 30, 2026
Showing 1–50
of 73 positions by value
· page 1 of 2
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RPRX |
Royalty Pharma plc
Healthcare
|
Held | 11,000 | $616,770 | 2.27% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Reduced | 25,000 | $606,500 | 2.23% | |
| INCY |
Incyte Corp
Healthcare
|
Held | 5,300 | $600,808 | 2.21% | |
| ARGX |
Argenx SE
Healthcare
|
Held | 641 | $594,700 | 2.19% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Held | 8,000 | $585,120 | 2.15% | |
| RAPP |
Rapport Therapeutics, Inc.
Healthcare
|
Held | 14,000 | $583,380 | 2.14% | |
| RARE |
Ultragenyx Pharmaceutical Inc.
Healthcare
|
Reduced | 17,000 | $567,630 | 2.09% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Held | 30,000 | $559,500 | 2.06% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Reduced | 23,000 | $556,600 | 2.05% | |
| TGTX |
Tg Therapeutics, Inc.
Healthcare
|
Reduced | 10,000 | $549,400 | 2.02% | |
| HALO |
Halozyme Therapeutics, Inc.
Healthcare
|
Reduced | 7,000 | $547,890 | 2.01% | |
| IONS |
Ionis Pharmaceuticals Inc
Healthcare
|
Held | 6,800 | $539,172 | 1.98% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Reduced | 15,000 | $518,700 | 1.91% | |
| ARQT |
Arcutis Biotherapeutics, Inc.
Healthcare
|
Held | 19,700 | $516,534 | 1.90% | |
| AUPH |
Aurinia Pharmaceuticals Inc.
Healthcare
|
Held | 30,000 | $509,100 | 1.87% | |
| NBIX |
Neurocrine Biosciences Inc
Healthcare
|
Reduced | 3,000 | $505,620 | 1.86% | |
| IMVT |
Immunovant, Inc.
Healthcare
|
Reduced | 13,000 | $500,890 | 1.84% | |
| ACAD |
Acadia Pharmaceuticals Inc
Healthcare
|
Held | 19,766 | $500,079 | 1.84% | |
| PTCT |
Ptc Therapeutics, Inc.
Healthcare
|
Held | 6,000 | $489,420 | 1.80% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Held | 13,000 | $483,730 | 1.78% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Held | 15,141 | $480,726 | 1.77% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
Reduced | 10,000 | $470,400 | 1.73% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Held | 12,000 | $464,400 | 1.71% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 4,000 | $458,680 | 1.69% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Held | 20,000 | $444,200 | 1.63% | |
| ALNY |
Alnylam Pharmaceuticals, Inc.
Healthcare
|
Held | 1,465 | $441,008 | 1.62% | |
| TARS |
Tarsus Pharmaceuticals, Inc.
Healthcare
|
Held | 7,000 | $440,580 | 1.62% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
Held | 20,000 | $437,200 | 1.61% | |
| EXEL |
Exelixis, Inc.
Healthcare
|
Reduced | 8,000 | $435,280 | 1.60% | |
| CRNX |
Crinetics Pharmaceuticals, Inc.
Healthcare
|
Held | 11,000 | $411,620 | 1.51% | |
| NAMS |
NewAmsterdam Pharma Co N.V.
Healthcare
|
Reduced | 12,000 | $406,680 | 1.49% | |
| ASND |
Ascendis Pharma A/S
Healthcare
|
Reduced | 1,500 | $400,080 | 1.47% | |
| LQDA |
Liquidia Corp
Healthcare
|
NEW | 5,000 | $398,650 | 1.47% | |
| STOK |
Stoke Therapeutics, Inc.
Healthcare
|
Held | 12,000 | $392,640 | 1.44% | |
| VKTX |
Viking Therapeutics, Inc.
Healthcare
|
Reduced | 10,000 | $390,100 | 1.43% | |
| IMNM |
Immunome Inc.
Healthcare
|
Reduced | 18,000 | $381,420 | 1.40% | |
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
Held | 3,000 | $367,740 | 1.35% | |
| HRMY |
Harmony Biosciences Holdings, Inc.
Healthcare
|
Reduced | 10,000 | $364,100 | 1.34% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Held | 7,000 | $355,250 | 1.31% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
Reduced | 4,000 | $355,120 | 1.31% | |
| NTLA |
Intellia Therapeutics, Inc.
Healthcare
|
Reduced | 20,000 | $338,400 | 1.24% | |
| MDGL |
Madrigal Pharmaceuticals, Inc.
Healthcare
|
Held | 600 | $322,170 | 1.18% | |
| KNSA |
Kiniksa Pharmaceuticals International, plc
Healthcare
|
Reduced | 5,000 | $319,750 | 1.18% | |
| ALKS |
Alkermes plc.
Healthcare
|
Held | 6,000 | $314,370 | 1.16% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
Reduced | 10,000 | $312,600 | 1.15% | |
| ARDX |
Ardelyx, Inc.
Healthcare
|
Reduced | 60,000 | $306,000 | 1.12% | |
| VERA |
Vera Therapeutics, Inc.
Healthcare
|
Reduced | 7,000 | $300,370 | 1.10% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Reduced | 2,500 | $292,675 | 1.08% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Reduced | 3,000 | $285,510 | 1.05% | |
| SUPN |
Supernus Pharmaceuticals, Inc.
Healthcare
|
Held | 6,000 | $279,060 | 1.03% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.